Exelixis Inc
EXELHealthcare|Biotechnology|USA
$56.51
-0.60 (-1.05%)
DCF (FCF)
$29.26
Tangible Book
$7.38
Graham Number
$23.55
Earnings Power
$17.69
Clinical Trials (152)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01896479 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer | Medullary Thyroid Cancer | P4 | Active | 247 | RCT, Double-blind | Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg, Placebo tablet, Placebo capsule |
| NCT06082167 Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | P2P3 | Active | 600 | RCT, Double-blind | Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab |
| NCT03141177 A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | P3 | Active | 701 | RCT, Open-label | Nivolumab, Cabozantinib, Sunitinib, Ipilimumab |
| NCT05678673 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | Non-Clear Cell Renal Cell Carcinoma | P3 | Active | 317 | RCT, Open-label | XL092, Nivolumab, Sunitinib Malate |
| NCT03690388 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | Differentiated Thyroid Cancer | P3 | Active | 187 | RCT, Double-blind | Cabozantinib, Placebo |
| NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) | Carcinoma, Renal Cell | P3 | Recruiting | 758 | RCT, Double-blind | Belzutifan, Zanzalintinib, Placebo |
| NCT05425940 Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | Colorectal Cancer | P3 | Active | 901 | RCT, Open-label | XL092, Atezolizumab, Regorafenib |
| NCT07227402 A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) | Renal Cell Carcinoma | P3 | Recruiting | 904 | RCT, Open-label | Belzutifan, Zanzalintinib, Cabozantinib |
| NCT04446117 Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | Metastatic Prostate Cancer, Prostate Adenocarcinoma | P3 | Active | 575 | RCT, Open-label | Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone |
| NCT06943755 Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | P2P3 | Recruiting | 440 | RCT, Open-label | Zanzalintinib, Everolimus |
| NCT03937219 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | P3 | Active | 855 | RCT, Double-blind | Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo |
| NCT03755791 Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | Hepatocellular Carcinoma | P3 | Active | 837 | RCT, Open-label | Cabozantinib, Cabozantinib, Sorafenib, Atezolizumab |
| NCT03899155 Pan Tumor Rollover Study | Cancer | P2 | Recruiting | 1,500 | Open-label | Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab |
| NCT04963283 Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | Colorectal Adenocarcinoma, Colon Cancer | P2 | Active | 48 | Open-label | Cabozantinib, Nivolumab |
| NCT04289779 Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer | Bladder Cancer | P2 | Active | 46 | Open-label | Cabozantinib, Atezolizumab |
| NCT04412629 Cabozantinib in High Grade Neuroendocrine Neoplasms | High Grade Neuroendocrine Neoplasms | P2 | Active | 35 | Open-label | Cabozantinib |
| NCT07283731 Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma | Phase 2, Zanzalintinib | P2 | Recruiting | 20 | Open-label | Zanzalintinib, Pembrolizumab |
| NCT06568562 XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | P2 | Recruiting | 32 | Open-label | XL092 |
| NCT06937866 Maintenance Zanzalintinib With Etoposide After HDCT in GCT | Germ Cell Tumor | P1P2 | Recruiting | 38 | Open-label | Zanzalintinib, Etoposide Capsule |
| NCT04413123 Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma | P2 | Active | 60 | Open-label | Cabozantinib, Nivolumab, Ipilimumab |
| NCT01639508 Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Non-Small Cell Lung Cancer | P2 | Recruiting | 86 | Open-label | Cabozantinib |
| NCT07049926 Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | Renal Cell Carcinoma | P1P2 | Recruiting | 140 | Single-blind | Belzutifan, Zanzalintinib |
| NCT05931393 Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | RCC, Renal Cell Carcinoma | P2 | Recruiting | 18 | Open-label | Cabozantinib 80 MG |
| NCT05502315 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | Castration-resistant Prostate Cancer, Metastatic Cancer | P2 | Active | 47 | Open-label | Cabozantinib, Nivolumab |
| NCT04876456 A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | Germ Cell Tumor, Seminoma | P2 | Active | 50 | Open-label | Cabozantinib |
| NCT06794229 Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis | Locally Advanced Renal Cell Carcinoma | P2 | Recruiting | 69 | Open-label | Zanzalintinib, Nivolumab |
| NCT05048212 A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | Brain Metastases, Renal Cell Carcinoma | P2 | Recruiting | 20 | RCT, Open-label | Nivolumab, Ipilimumab, Cabozantinib |
| NCT04022343 Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma | P2 | Active | 22 | Open-label | Cabozantinib |
| NCT06835972 A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma | P1P2 | Recruiting | 43 | Open-label | Abemaciclib, Cabozantinib |
| NCT03541902 Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma | P2 | Active | 32 | RCT, Open-label | Cabozantinib, Sunitinib Malate |
| NCT07193550 A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) | Bone Sarcomas | P2 | Recruiting | 70 | Open-label | Zanzalintinib |
| NCT04164979 Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | Gastric Adenocarcinoma, GastroEsophageal Cancer | P2 | Active | 34 | Open-label | Cabozantinib, Pembrolizumab |
| NCT06959511 Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery | Neoadjuvant Treatment, Thyroid Cancer | P2 | Recruiting | 45 | Open-label | Zanzalintinib |
| NCT05135975 A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Neuroblastoma, Sarcoma | P2 | Recruiting | 86 | Open-label | Cabozantinib |
| NCT04551430 Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | P2 | Active | 105 | RCT, Open-label | Cabozantinib, Nivolumab, Ipilimumab |
| NCT04091750 Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | Melanoma | P2 | Active | 14 | Open-label | Nivolumab, Ipilimumab, Cabozantinib |
| NCT04322955 CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | Kidney Cancer, Renal Cell Carcinoma | P2 | Active | 38 | Open-label | Cabozantinib, Nivolumab |
| NCT05425004 Cabozantinib for Patients With Recurrent or Progressive Meningioma | Meningioma | P2 | Recruiting | 24 | Open-label | Cabozantinib |
| NCT04472767 Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | Hepatocellular Carcinoma, HCC | P2 | Recruiting | 35 | Open-label | Nivolumab, Ipilimumab, Cabozantinib |
| NCT03468218 Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma | P2 | Active | 36 | Open-label | Cabozantinib, Pembrolizumab |
| NCT05263050 Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma | P2 | Recruiting | 111 | Open-label | Cabozantinib, Nivolumab |
| NCT06926634 Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) | High Grade Neuroendocrine Neoplasms | P2 | Recruiting | 32 | Open-label | Zanzalintinib |
| NCT06698250 Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) | Hepatocellular Carcinoma | P2 | Recruiting | 40 | Open-label | Zanzalintinib, Durvalumab, Tremelimumab |
| NCT06863311 Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | P2 | Recruiting | 70 | RCT, Open-label | XL092, Nivolumab |
| NCT07428616 A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | Meningioma | P2 | Recruiting | 100 | Open-label | Zanzalintinib |
| NCT03539822 Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | Gastric Cancer, Esophageal Adenocarcinoma | P1P2 | Recruiting | 117 | Open-label | Cabozantinib, Durvalumab, Tremelimumab |
| NCT02721459 XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | Melanoma, Skin Cancer | P1 | Active | 26 | Open-label | XL888, Vemurafenib, Cobimetinib |
| NCT06545331 Study of XB010 in Subjects With Solid Tumors | Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer | P1 | Recruiting | 396 | Open-label | XB010, Pembrolizumab |
| NCT06795009 Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Uterine Cancer, Endometrial Cancer | P1 | Recruiting | 36 | Open-label | Zanzalintinib, Paclitaxel |
| NCT06132945 A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | Metastatic Renal Cell Carcinoma, Brain Metastases | P1 | Active | 2 | Open-label | Cabozantinib |
| NCT03845166 A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | Neoplasm Malignant, Renal Cell Carcinoma | P1 | Active | 325 | Open-label | XL092, Atezolizumab, Avelumab |
| NCT04878029 Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma | P1 | Recruiting | 32 | Open-label | Cabozantinib S-malate, Enfortumab Vedotin |
| NCT05932862 A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 429 | Open-label | XL309, Olaparib |
| NCT03170960 Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Urothelial Carcinoma, Renal Cell Carcinoma | P1 | Active | 914 | Open-label | cabozantinib, atezolizumab, cabozantinib, cabozantinib |
| NCT06902376 XL092 and Cemiplimab in BRAF WT Thyroid Cancer | Anaplastic Thyroid Cancer, Thyroid Cancer | P1 | Recruiting | 12 | Open-label | Cemiplimab, XL092 |
| NCT06962332 Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) | Hepatic Impairment, Moderate Hepatic Impairment | P1 | Recruiting | 20 | Open-label | Zanzalintinib |
| NCT06912087 Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC | Head and Neck Neoplasms, Carcinoma, Squamous Cell | P1 | Recruiting | 36 | Open-label | Zanzalintinib, Cetuximab, Pembrolizumab |
| NCT06968988 Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | P1 | Recruiting | 18 | Open-label | Zanzalintinib, Ipilimumab, Nivolumab |
| NCT05176483 Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) | P1 | Recruiting | 1,314 | Open-label | Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab, Nivolumab, Nivolumab + Relatlimab |
| NCT06156410 Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | Ewing Sarcoma, Osteosarcoma | P1 | Recruiting | 30 | Open-label | Cabozantinib |
| NCT06957431 Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | Advanced Leiomyosarcoma, Adipocytic Sarcoma | P1 | Recruiting | 18 | Open-label | Zanzalintinib, Eribulin |
| NCT07123103 A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Solid Tumors | P1 | Recruiting | 150 | Open-label | XB371 |
| NCT06952010 A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | Solid Tumor, Advanced Solid Tumor | P1 | Recruiting | 303 | Open-label | XB628, Zanzalintinib |
| NCT05249114 Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | Neuroendocrine Tumors | P1 | Active | 6 | Open-label | Cabozantinib, Lu-177 |
| NCT04919122 Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Active | 468 | — | — | |
| NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | Cancer, Renal Cell Carcinoma (RCC) | P3 | Not Yet Recruiting | 5,000 | Open-label | Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide |
| NCT01865747 A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | P3 | Completed | 658 | RCT, Open-label | Cabozantinib tablets, Everolimus (Afinitor) tablets |
| NCT01522443 Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | Prostate Cancer, Castration Resistant Prostate Cancer | P3 | Terminated | 119 | RCT, Double-blind | cabozantinib, mitoxantrone, prednisone |
| NCT01605227 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 | Prostate Cancer, Castration Resistant Prostate Cancer | P3 | Completed | 1,028 | RCT, Double-blind | cabozantinib, prednisone |
| NCT00704730 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer | Thyroid Cancer | P3 | Completed | 330 | RCT, Double-blind | XL184, Placebo |
| NCT04471428 Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | Carcinoma, Non-Small-Cell Lung | P3 | Completed | 366 | RCT, Open-label | Cabozantinib, Atezolizumab, Docetaxel |
| NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Hepatocellular Carcinoma | P3 | Completed | 707 | RCT, Double-blind | Cabozantinib tablets, Placebo tablets |
| NCT04338269 A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment | Carcinoma, Renal Cell | P3 | Terminated | 522 | RCT, Open-label | Atezolizumab, Cabozantinib |
| NCT02260531 Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases | Breast Cancer, Brain Tumor - Metastatic | P2 | Completed | 36 | Open-label | Cabozantinib, Trastuzumab |
| NCT05859217 A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | Lung Cancer, NSCLC Stage IV | P2 | Not Yet Recruiting | 40 | Open-label | Cabozantinib, Atezolizumab |
| NCT04151563 A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | Carcinoma, Non-small Cell Lung Cancer | P1P2 | Withdrawn | — | RCT, Open-label | nivolumab, ipilimumab, cabozantinib, docetaxel, ramucirumab, lucitanib |
| NCT00838890 A Study of BMS-863233 in Patients With Hematologic Cancer | Refractory Hematologic Cancer | P1P2 | Terminated | 11 | Open-label | Cdc7-inhibitor (BMS-863233), Cdc7-inhibitor (BMS-863233) |
| NCT05200143 Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | Refractory Cutaneous Melanoma | P2 | Terminated | 4 | Open-label | Ipilimumab, Nivolumab, Cabozantinib |
| NCT01441947 Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer | Breast Cancer | P2 | Completed | 68 | Open-label | Cabozantinib, Fulvestrant |
| NCT07043608 Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases | Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | P2 | Not Yet Recruiting | 20 | Open-label | Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA) |
| NCT03964337 Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer | Prostate Cancer, Prostate Cancer Adenocarcinoma | P2 | Terminated | 3 | RCT, Open-label | Cabozantinib |
| NCT07226063 Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer | Hepatocellular Carcinoma, Liver Cancer | P2 | Not Yet Recruiting | 16 | Open-label | Durvalumab, Zanzalintinib |
| NCT07218666 Zanzalintinib in Men With Aggressive Variant Prostate Cancer | Aggressive Variant Prostate Carcinoma | P2 | Not Yet Recruiting | 30 | Open-label | Zanzalintinib |
| NCT00570635 A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib | Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms | P2 | Completed | 16 | RCT, Open-label | XL820, XL820 |
| NCT04197310 Cabozantinib and Nivolumab for Carcinoid Tumors | Carcinoid Tumor, Carcinoid Tumor of GI System | P2 | Completed | 19 | Open-label | Nivolumab, Cabozantinib |
| NCT05039736 A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy | Hepatocellular Carcinoma, Liver Cancer | P2 | Withdrawn | — | RCT, Open-label | Cabozantinib, Nivolumab |
| NCT05052723 Cabozantinib and Pembrolizumab in Metastatic Pancreas | Pancreatic Cancer | P2 | Completed | 21 | Open-label | Cabozantinib, Pembrolizumab |
| NCT01995058 Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | Prostate Cancer, Castration Resistant Prostate Cancer | P2 | Terminated | 54 | RCT, Open-label | cabozantinib, abiraterone, prednisone |
| NCT01428219 Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone | Prostate Cancer Metastatic | P2 | Terminated | 25 | Open-label | Cabozantinib |
| NCT02036476 Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Merkel Cell Carcinoma, Skin Cancer | P2 | Terminated | 8 | Open-label | Cabozantinib |
| NCT07185945 Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy | Advanced Urothelial Carcinoma | P2 | Not Yet Recruiting | 44 | Open-label | Zanzalintinib |
| NCT00940225 Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | Solid Tumors, Cancer | P2 | Completed | 730 | RCT, Double-blind | Cabozantinib, Placebo |
| NCT04442581 Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | P2 | Terminated | 2 | Open-label | Cabozantinib S-malate, Pembrolizumab |
| NCT01954745 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | Bile Duct Cancer, Intrahepatic Cholangiocarcinoma | P2 | Completed | 19 | Open-label | Cabozantinib |
| NCT03534804 Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma | Metastatic Urothelial Carcinoma, Bladder Cancer | P2 | Completed | 37 | Open-label | Cabozantinib, Pembrolizumab |
| NCT02795156 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Non-small Cell Lung Carcinoma, Urothelial Carcinoma | P2 | Completed | 100 | Open-label | Afatinib, Regorafenib, Cabozantinib |
| NCT01866293 Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | Relapsed or Refractory Multiple Myeloma | P1P2 | Completed | 11 | Open-label | Cabozantinib (XL184) |
| NCT00886782 A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | Advanced Solid Cancers, Metastatic Cancer | P1P2 | Terminated | 11 | Open-label | Cdc7-inhibitor |
| NCT03957551 Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | Advanced Metastatic Melanoma | P1P2 | Terminated | 28 | Open-label | Cabozantinib, Pembrolizumab |
| NCT03213626 Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic | P2 | Terminated | 7 | Open-label | Cabozantinib 40 MG, Erlotinib 100Mg Tab |
| NCT07511504 Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | P2 | Not Yet Recruiting | 40 | Open-label | Durvalumab, Tremelimumab, Zanzalintinib |
| NCT03316586 A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | Breast Cancer | P2 | Completed | 18 | Open-label | Nivolumab, Cabozantinib |
| NCT04631744 Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Prostate Cancer | P2 | Terminated | 4 | Open-label | Cabozantinib |
| NCT04220229 Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities | P1P2 | Terminated | 6 | Open-label | Cabozantinib S-malate |
| NCT07623460 Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer | mCRPC (Metastatic Castration-resistant Prostate Cancer) | P2 | Not Yet Recruiting | 30 | Open-label | Zanzalintinib |
| NCT00704288 Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | Glioblastoma Multiforme | P2 | Completed | 222 | Open-label | XL184 |
| NCT02132598 Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain | P2 | Terminated | 5 | Open-label | cabozantinib |
| NCT00596648 A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | P1P2 | Completed | 92 | RCT, Open-label | XL184, erlotinib |
| NCT01630590 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer | Prostate Cancer | P2 | Completed | 62 | Open-label | Cabozantinib, Androgen Ablation Therapy |
| NCT04497038 Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | Advanced Adult Hepatocellular Carcinoma | P1P2 | Terminated | 3 | Open-label | Cabozantinib |
| NCT04230954 Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | Cervical Cancer, Recurrent Cervical Cancer | P2 | Terminated | 5 | Open-label | Cabozantinib 40 MG oral once a day, Pembrolizumab 200 mg IV every 3 weeks |
| NCT01811212 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma | P2 | Completed | 25 | Open-label | Cabozantinib S-malate |
| NCT01068782 Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse | Astrocytic Tumors | P2 | Terminated | 19 | RCT, Open-label | Cabozantinib |
| NCT07484139 H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) | Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer | P2 | Not Yet Recruiting | 26 | Open-label | XL092, Pembrolizumab |
| NCT06191796 Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | P1 | Terminated | 25 | Open-label | zanzalintinib, AB521, Nivolumab |
| NCT02008383 Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer | Colorectal Cancer | P1 | Completed | 29 | Open-label | Panitumumab, Cabozantinib |
| NCT00460278 Study of XL418 in Adults With Solid Tumors | Cancer, Solid Tumors | P1 | SUSPENDED | 63 | Open-label | XL418 |
| NCT00464113 Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia | Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | P1 | Terminated | 49 | Open-label | XL228 |
| NCT00451880 Study of XL281 in Adults With Solid Tumors | Cancer, Non-small-cell Lung Cancer | P1 | Completed | 180 | Open-label | XL281, famotidine |
| NCT04726332 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Neoplasm Malignant, Epithelial Ovarian Cancer | P1 | Terminated | 52 | Open-label | XL102, Fulvestrant, Abiraterone, Prednisone |
| NCT03611595 Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors | Solid Tumor | P1 | Completed | 15 | Open-label | Cabozantinib, 13-cis-retinoic acid |
| NCT00475917 A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies | Cancer, Lymphoma | P1 | Terminated | 28 | Open-label | XL844, Gemcitabine |
| NCT00350831 Study of XL820 Given Orally Daily to Subjects With Solid Tumors | Cancer | P1 | Completed | 30 | Open-label | XL820 |
| NCT06630247 A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors | Solid Cancers, Solid Tumor Cancer | P1 | Terminated | 9 | Open-label | XL495, ADC cytotoxic agents |
| NCT01100619 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | Papillary Thyroid Cancer, Follicular Thyroid Cancer | P1 | Completed | 40 | Open-label | rosiglitazone, XL184 |
| NCT03095781 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | P1 | Completed | 47 | Open-label | XL888, Pembrolizumab |
| NCT00670189 A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer | Hedgehog Pathway, Smoothened | P1 | Completed | 53 | Open-label | BMS-833923 (XL139) |
| NCT00522574 A Safety Study of XL019 in Adults With Myelofibrosis | Myeloproliferative Disorders, Myelofibrosis | P1 | Terminated | 100 | Open-label | XL019 |
| NCT00526838 Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | Cancer, Lymphoma | P1 | Terminated | 84 | Open-label | XL228 |
| NCT00909402 A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas | Stomach Neoplasms, Esophageal Neoplasms | P1 | Completed | 39 | Open-label | BMS-833923, Cisplatin, Capecitabine |
| NCT05613894 Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | P1 | SUSPENDED | 33 | Open-label | Cabozantinib |
| NCT00927875 A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer | Small Cell Lung Carcinoma | P1 | Completed | 5 | Open-label | BMS-833923, Carboplatin, Etoposide |
| NCT04925284 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Non Small Cell Lung Cancer, Cervical Cancer | P1 | Completed | 269 | RCT, Open-label | XB002, Nivolumab, Bevacizumab |
| NCT00215605 Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies | Lymphoma, Cancer | P1 | Completed | 85 | Open-label | XL184 |
| NCT00796484 Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors | Cancer | P1 | Terminated | 33 | Open-label | XL888 |
| NCT00129571 Study of XL820 in Adults With Solid Tumors | Cancer | P1 | Completed | — | Open-label | XL820 |
| NCT05144347 Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL) | P1 | Terminated | 2 | Open-label | XL114 |
| NCT00234481 Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P1 | Terminated | — | Open-label | XL844 |
| NCT01961765 Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | P1 | Completed | 18 | Open-label | cabozantinib |
| NCT01493869 Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects | Healthy, Hepatic Impairment | P1 | Completed | 26 | Open-label | cabozantinib |
| NCT04477512 Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) | Metastatic Hormone Refractory Prostate Cancer | P1 | Completed | 18 | Open-label | Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone |
| NCT01657591 Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | Melanoma | P1 | Completed | 21 | Open-label | XL888, Vemurafenib |
| NCT00884546 Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma | Advanced Cancer, Various, NOS | P1 | Completed | 27 | Open-label | BMS-833923, Lenalidomide, Dexamethasone, Bortezomib |
| NCT01761773 A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function | Healthy, Renal Impairment | P1 | Completed | 32 | Open-label | cabozantinib |
| NCT03299946 Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | Locally Advanced Hepatocellular Carcinoma | P1 | Completed | 15 | Open-label | Cabozantinib, Nivolumab |
| NCT00704392 Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors | Cancer, Non-small-cell Lung Cancer | P1 | Withdrawn | — | Open-label | XL647, XL147 |
| NCT00595829 A Phase 1 Study of XL019 in Adults With Polycythemia Vera | Polycythemia Vera | P1 | Terminated | 3 | Open-label | XL019 |
| NCT07187869 Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | Clear Cell Renal Cell Carcinoma | P1 | Not Yet Recruiting | 16 | Open-label | Cabozantinib, Nivolumab |
| NCT00960492 Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | Glioblastoma, Giant Cell Glioblastoma | P1 | Completed | 26 | Open-label | XL184, temozolomide, temozolomide, temozolomide |
| NCT01553656 Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer | Solid Tumors, Cancer | P1 | Completed | 85 | Open-label | cabozantinib capsules, cabozantinib tablets |
| NCT01683110 Expanded Access of Cabozantinib in Medullary Thyroid Cancer | Medullary Thyroid Cancer | APPROVED_FOR_MARKETING | — | — | cabozantinib | |
| NCT03867045 Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer | Metastatic Renal Cell Carcinoma Treated With Cabozantinib | N/A | Terminated | 1 | Open-label | — |